Tirzepatide shows promise in reducing weight and preventing diabetes progression in people with obesity and prediabetes, with ...

A new study has shed light on the health risks faced by people who stop using weight-loss medications Ozempic or Wegovy.

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

About 1 in 8 U.S. adults have taken Ozempic or similar medications used to treat Type 2 diabetes and obesity. While these ...

More than 48 million Americans 12 years or older had a substance use disorder in 2022, yet only 24 percent received treatment ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief executive officer Michele Buck told analysts in a conference call on fiscal 2024 ...

(Irwin, 11/13) Yahoo Finance: Hims & Hers Launches GLP-1 Tracker In Response To FDA's Shortage Decision Hims & Hers is launching a new GLP-1 tracker in its efforts to fight back against the FDA’s ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...